📗 Cite This Artifact
vip-vasoactive-intestinal-peptide-signaling-neurodegeneration
Vasoactive Intestinal Peptide (VIP) Signaling Pathway in Neurodegeneration
Overview
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems. VIP acts as a neurotransmitter, neuromodulator, and neuroprotective factor. VIP receptors (VPAC1, VPAC2) are expressed throughout the brain, including in regions vulnerable to neurodegeneration. VIP signaling has shown promising neuroprotective, anti-inflammatory, and immunomodulatory effects in models of Alzheimer's, Parkinson's, and other neurodegenerative diseases[@gozes2009].
VIP Biology
Structure and Distribution
VIP is encoded by the VIP gene and is expressed in multiple brain regions[@said1984]:
- Cerebral [cortex](/brain-regions/cortex)
- [Hippocampus](/brain-regions/hippocampus)
- Hypothalamus
- Brainstem
- Enteric nervous system
VIP is also produced by immune cells, including T cells, B cells, and macrophages, where it functions as an immunomodulatory peptide.
Receptor Signaling
VIP signals through two main receptor types[@harmar2012]:
- VPAC1: High affinity for VIP, widely distributed throughout the brain
- VPAC2: Modulates circadian rhythm and behavior
```mermaid
flowchart TD
AVIP --> BVPA["VPAC1"]
AVIP --> CVPA["VPAC2"]
B --> DGalphas
C --> D
D --> EAdenylylCyclase
E --> F["upcAMP"]
F --> GPKA
G --> HCREB
H --> IGeneTranscription
G --> JERK1/2
J --> KCellSurvival
J --> L"Neuroplasticity"
Vasoactive Intestinal Peptide (VIP) Signaling Pathway in Neurodegeneration
Overview
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems. VIP acts as a neurotransmitter, neuromodulator, and neuroprotective factor. VIP receptors (VPAC1, VPAC2) are expressed throughout the brain, including in regions vulnerable to neurodegeneration. VIP signaling has shown promising neuroprotective, anti-inflammatory, and immunomodulatory effects in models of Alzheimer's, Parkinson's, and other neurodegenerative diseases[@gozes2009].
VIP Biology
Structure and Distribution
VIP is encoded by the VIP gene and is expressed in multiple brain regions[@said1984]:
- Cerebral [cortex](/brain-regions/cortex)
- [Hippocampus](/brain-regions/hippocampus)
- Hypothalamus
- Brainstem
- Enteric nervous system
VIP is also produced by immune cells, including T cells, B cells, and macrophages, where it functions as an immunomodulatory peptide.
Receptor Signaling
VIP signals through two main receptor types[@harmar2012]:
- VPAC1: High affinity for VIP, widely distributed throughout the brain
- VPAC2: Modulates circadian rhythm and behavior
Key signaling pathways:[@moody2011]
- cAMP/PKA/CREB: Gene transcription and neuroprotection
- ERK1/2: Cell survival and neuroplasticity
- PI3K/Akt: Anti-apoptotic signaling
- p38 MAPK: Anti-inflammatory effects
VIP Signaling Mechanisms
cAMP/PKA/CREB Pathway
VIP binding to VPAC receptors activates Gαs proteins, stimulating adenylyl cyclase and increasing intracellular cAMP levels. This activates protein kinase A (PKA), which phosphorylates the cAMP response element-binding protein (CREB). Phosphorylated CREB translocates to the nucleus and promotes transcription of neuroprotective genes, including:[@gozes2003]
- Brain-derived neurotrophic factor ([BDNF](/proteins/bdnf-protein))
- Anti-oxidant enzymes (SOD, catalase)
- Anti-apoptotic proteins (Bcl-2)
- Synaptic plasticity proteins
PI3K/Akt Survival Pathway
VIP also activates the PI3K/Akt pathway through cAMP-mediated activation of Epac (exchange protein activated by cAMP). Epac activates Rap1, which then activates PI3K, leading to Akt phosphorylation. Akt phosphorylates multiple targets that promote cell survival:[@suh2005]
- GSK-3β inhibition (prevents tau phosphorylation)
- Bad inactivation (pro-apoptotic)
- NF-κB activation (pro-survival gene expression)
- mTOR activation (protein synthesis)
Anti-inflammatory Signaling
VIP exerts potent anti-inflammatory effects through multiple mechanisms[@delgado2004]:
- Inhibition of NF-κB signaling in microglia
- Suppression of iNOS and COX-2 expression
- Reduction of pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α)
- Promotion of M2 microglial phenotype
- Increased IL-10 production
Role in Alzheimer's Disease
Amyloid Pathology
VIP affects [amyloid-beta](/proteins/amyloid-beta) (Aβ) metabolism through multiple mechanisms[@pass2006]:
- Reduced Aβ-induced neurotoxicity
- Modulation of [APP](/entities/app-protein) processing toward non-amyloidogenic pathway
- Enhanced neuronal survival against Aβ
- Promotion of Aβ clearance
Studies have shown that VIP treatment reduces Aβ production by modulating α-secretase activity, shifting APP processing away from β- and γ-secretase cleavage. This represents a potential therapeutic approach for reducing amyloid plaque formation in AD.
Synaptic Function
VIP enhances synaptic plasticity through several mechanisms[@pham2002]:
- Improved hippocampal long-term potentiation ([LTP](/mechanisms/long-term-potentiation))
- Enhanced GABAergic signaling
- Increased dendritic spine density
- Better cognitive function in AD models
VIP-positive interneurons in the hippocampus play a critical role in regulating circuit excitability and plasticity. Loss of VIP signaling in AD may contribute to hippocampal dysfunction and memory deficits.
Neuroinflammation
VIP has potent anti-inflammatory effects in the AD brain[@brenneman2003]:
- Reduced microglial activation
- Decreased pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α)
- Shift from M1 (pro-inflammatory) to M2 (neuroprotective) microglial phenotype
- Reduced astrogliosis
Chronic neuroinflammation is a major contributor to AD progression. VIP's ability to suppress neuroinflammation makes it an attractive therapeutic candidate.
Trophic Effects
VIP provides neurotrophic support in AD[@gozes1997]:
- Enhanced neurite outgrowth
- Protection against oxidative stress
- Support for cholinergic neurons
- Promotion of synaptic protein expression
The cholinergic system is particularly vulnerable in AD, and VIP has been shown to protect cholinergic neurons from degeneration.
Role in Parkinson's Disease
Dopaminergic Neuroprotection
VIP protects dopaminergic neurons through multiple pathways[@offen2000]:
- Reduced 6-OHDA toxicity
- Preservation of tyrosine hydroxylase (TH)-positive neurons
- Improved motor function in PD models
- Protection against rotenone-induced toxicity
VIP's neuroprotective effects on dopaminergic neurons may be mediated through cAMP/PKA/CREB signaling and upregulation of neurotrophic factors.
Neuroinflammation
Anti-inflammatory effects in PD include[@kong2012]:
- Modulation of microglial activation
- Reduced neuroinflammation in substantia nigra
- Decreased dopaminergic neuron loss
- Protection of the blood-brain barrier
The anti-inflammatory properties of VIP are particularly relevant in PD, where microglial activation plays a key role in dopaminergic neuron degeneration.
Alpha-Synuclein Modulation
Recent research suggests VIP may affect [alpha-synuclein](/proteins/alpha-synuclein) pathology[@samaranch2014]:
- Reduced alpha-synuclein aggregation
- Enhanced autophagy-mediated clearance
- Protection against synuclein-induced toxicity
These findings suggest VIP may have disease-modifying potential in PD by targeting the core pathological protein.
Role in Other Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis (ALS)
VIP shows promise in ALS models[@nguyen2001]:
- Protection of motor neurons
- Reduced gliosis
- Extended survival in SOD1 mutant mice
- Modulation of immune responses
Huntington's Disease
In HD models, VIP provides[@maqbool2013]:
- Neuroprotection against mHTT toxicity
- Improvement in behavioral deficits
- Reduction in striatal atrophy
- Enhanced BDNF signaling
Multiple Sclerosis
VIP's immunomodulatory properties are relevant in demyelinating diseases[@lerner2007]:
- Suppression of autoimmune responses
- Protection of oligodendrocytes
- Promotion of remyelination
- Reduction in clinical severity
Therapeutic Potential
VIP Analogues and Agonists
Several VIP receptor agonists have been developed for clinical use[@mendoza2010]:
- Aviptadil (VIP analog): Used in clinical trials for various conditions
- Ro 25-1392: Selective VPAC2 agonist
- BAY 55-9837: Mixed VPAC1/VPAC2 agonist
See [VIP/VPAC Receptor Modulators for Neurodegeneration](/therapeutics/vip-vpac-receptor-modulators) for detailed therapeutic development information.
Delivery Challenges
Effective VIP-based therapies face several challenges[@bundgaard2012]:
- Short half-life in circulation
- Poor blood-brain barrier penetration
- Rapid degradation by proteases
Alternative Strategies
To overcome delivery challenges, researchers are exploring[@kumar2015]:
- Intranasal delivery
- Peptide conjugates for BBB transport
- Gene therapy approaches
- Cell-penetrating peptide fusions
Preclinical and Clinical Evidence
Animal Models
VIP and its analogs have shown efficacy in multiple animal models of neurodegeneration:
- 5xFAD mouse model of AD: Reduced amyloid plaques, improved cognition
- MPTP mouse model of PD: Protected dopaminergic neurons
- SOD1 model of ALS: Extended survival
- 3-NP model of HD: Improved motor function
Clinical Trials
Several clinical trials have investigated VIP-based therapies[@clinicaltrialsgov]:
- Phase 2 trial in AD: Safety established, signals of efficacy
- Phase 1 trial in PD: Safety confirmed
- trials in MS: Immunomodulatory effects observed
Future Directions
Combination Therapies
VIP may be particularly effective in combination approaches:
- With [BDNF](/proteins/bdnf-protein) or other neurotrophic factors
- With anti-amyloid antibodies
- With anti-inflammatory agents
- With stem cell therapies
Biomarker Development
Identifying biomarkers for VIP therapeutic response:
- cAMP levels in CSF
- VPAC receptor expression
- Microglial activation markers
- Neuroinflammatory biomarkers
Personalized Medicine
Future applications may include:
- VPAC receptor genotyping
- Stratification by neuroinflammatory phenotype
- Combination with targeted small molecules
Related Pathways and Mechanisms
- [Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation)
- [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation)
- [Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling)
- [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
- [APP Processing Pathways](/mechanisms/app-processing)
- [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-pd)
Detailed Molecular Mechanisms
G Protein Coupling and Second Messenger Systems
VIP signaling is mediated through VPAC1 and VPAC2 receptors, which belong to the class B (secretin) family of G protein-coupled receptors (GPCRs)[@couvineau2010]. Upon VIP binding, these receptors undergo conformational changes that activate Gαs proteins, leading to dissociation of Gαs from the Gβγ dimer. The free Gαs subunit then activates adenylyl cyclase, catalyzing the conversion of ATP to cyclic AMP (cAMP)[@miller2008].
The cAMP second messenger system activates multiple downstream effectors:
Protein Kinase A (PKA): PKA is a tetrameric enzyme consisting of two regulatory and two catalytic subunits. Binding of four cAMP molecules causes dissociation of the catalytic subunits, which then phosphorylate target proteins including CREB, glycogen synthase, phosphofructokinase, and various transcription factors[@sklvik2009].
Exchange Protein Activated by cAMP (Epac): Epac functions as a cAMP-dependent guanine nucleotide exchange factor. Epac activation leads to activation of Rap1, a small GTPase that promotes PI3K/Akt signaling[@bos2007]. This pathway is critical for anti-apoptotic signaling and cell survival.
cAMP-gated ion channels: cAMP can directly modulate ion channel activity, affecting neuronal excitability and synaptic transmission.
Calcium Signaling Modulation
VIP signaling significantly impacts intracellular calcium dynamics[^26]:
Voltage-gated calcium channels: VIP modulates L-type and N-type calcium channels through PKA-dependent phosphorylation.
Intracellular calcium release: Through ryanodine receptor activation, VIP can stimulate calcium release from endoplasmic reticulum stores.
Calcium binding proteins: VIP upregulates calbindin and parvalbumin, protecting neurons from calcium-induced toxicity.
MAPK/ERK Pathway Activation
VIP activates the MAPK/ERK pathway through both cAMP-dependent and independent mechanisms[@huang2010]. The ERK1/2 pathway contributes to CREB phosphorylation and gene transcription, neuronal differentiation, synaptic plasticity, and cell survival through BAD phosphorylation.
NF-κB Inhibition
One of VIP's most important anti-inflammatory mechanisms is inhibition of NF-κB signaling[@karin2009]. VIP prevents IκB degradation, maintaining NF-κB in the cytoplasm, reduces NF-κB DNA binding activity, and suppresses NF-κB target gene expression. This inhibition affects pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α), iNOS and COX-2 expression, matrix metalloproteinases, and adhesion molecules.
Alzheimer's Disease: Expanded Mechanisms
Amyloid Precursor Protein Processing
VIP modulates amyloid precursor protein (APP) processing through multiple mechanisms[@obregon2011]. VIP promotes non-amyloidogenic processing by enhancing α-secretase activity, increasing production of sAPPα, which has neuroprotective properties. VIP may also reduce amyloidogenic processing by suppressing β- and γ-secretase activity, and enhances microglial phagocytosis of Aβ, promoting clearance of existing plaques.
Tau Pathology
VIP affects tau phosphorylation through several pathways[@mandelkow2012]. VIP-activated Akt phosphorylates and inhibits GSK-3β, a key kinase responsible for tau phosphorylation. VIP also enhances protein phosphatase 2A (PP2A) activity, promoting tau dephosphorylation, and promotes microtubule stability, counteracting tau-induced cytoskeletal disruption.
Synaptic Plasticity
VIP plays a crucial role in hippocampal synaptic plasticity[@malenka2009]. VIP enhances long-term potentiation (LTP) through increased presynaptic release, enhanced NMDA receptor function, and CREB-mediated gene expression. VIP also modulates long-term depression (LTD), maintaining synaptic homeostasis, and promotes dendritic spine density and morphological maturation through BDNF-dependent mechanisms.
Cholinergic System
VIP interactions with the cholinergic system are particularly relevant for AD[@hampel2020]. VIP protects basal forebrain cholinergic neurons from degeneration, enhances choline acetyltransferase (ChAT) activity, and improves cholinergic synaptic transmission.
Parkinson's Disease: Expanded Mechanisms
Mitochondrial Protection
VIP protects dopaminergic neurons from mitochondrial dysfunction[@schapira2009]. VIP preserves mitochondrial Complex I activity, which is specifically affected in PD, enhances antioxidant enzyme expression reducing reactive oxygen species, promotes PGC-1α expression enhancing mitochondrial biogenesis, and maintains mitochondrial membrane potential preventing apoptosis initiation.
Alpha-Synuclein Aggregation
VIP modulates alpha-synuclein pathology through[@spillantini2009]. VIP reduces alpha-synuclein oligomerization, activates autophagy pathways enhancing clearance of alpha-synuclein aggregates, and may reduce interneuronal spread of alpha-synuclein pathology.
Neuroinflammation in PD
VIP's anti-inflammatory effects are particularly relevant in PD[@prinz2011]. VIP shifts microglia from M1 to M2 phenotype, decreases TNF-α, IL-1β, and IL-6 in the substantia nigra, and modulates peripheral and CNS-infiltrating T cell responses.
Blood-Brain Barrier Protection
VIP protects the blood-brain barrier in PD models[@zlokovic2011]. VIP preserves BBB tight junction integrity, protects brain endothelial cells from toxic insult, and regulates BBB transport of nutrients and drugs.
Amyotrophic Lateral Sclerosis
Motor Neuron Protection
VIP provides motor neuron protection through multiple pathways[@boillee2006]. VIP extends survival in SOD1 mutant mouse models, protects against glutamate-induced excitotoxicity, and preserves axonal integrity preventing degeneration.
Glial Modulation
VIP modulates glial responses in ALS[@ilieva2009]. VIP regulates astrocytic glutamate transport, reduces harmful microglial activation, and supports oligodendrocyte function.
Huntington's Disease
Mutant Huntingtin Interaction
VIP affects mutant huntingtin (mHTT) toxicity[@bates2013]. VIP reduces mHTT aggregation, counteracts mHTT-induced transcriptional dysregulation, and enhances BDNF expression countering the BDNF deficit in HD.
Motor Function
VIP improves motor function in HD models[@ferrante2009]. VIP treatment improves rotarod performance, reduces striatal neuron loss, and ameliorates chorea and other HD symptoms.
Biomarker Development
Diagnostic Biomarkers
VIP-related biomarkers may aid in diagnosis[@zlokovic2011a]. Measurements include CSF and blood VIP levels, peripheral monocyte VPAC1/2 expression, and cAMP responsiveness to VIP stimulation.
Prognostic Biomarkers
VIP-related markers may predict progression[@blennow2010]. These include correlation with disease progression rate, VIP-related changes on MRI or PET, and correlations between VIP levels and clinical outcomes.
Therapeutic Monitoring
VIP therapy monitoring includes[@jack2010]. Target engagement through measuring downstream signaling effects, biomarker changes tracking inflammatory and neurodegenerative markers, and clinical endpoints correlating VIP levels with clinical improvement.
Therapeutic Delivery Strategies
Peptide Stability
VIP faces significant stability challenges[@werle2008]. VIP is rapidly degraded by proteases in circulation. Strategies for half-life extension include D-amino acid substitutions, peptide cyclization, and albumin fusion proteins. Development of protease-resistant VIP analogs is ongoing.
Blood-Brain Barrier Penetration
BBB penetration remains a key challenge[@pardridge2010]. Intranasal delivery bypasses BBB for direct nose-to-brain transport. Focused ultrasound temporarily opens BBB for drug delivery. Receptor-mediated transport utilizes endogenous BBB transporters. Nanoparticle delivery encapsulates drug in brain-targeting nanoparticles.
Clinical Development
Current clinical trial status[@cummings2021]. Phase 1/2 trials have established safety. Ongoing trials exist in AD and PD. Combination therapies and biomarker-driven approaches are future directions.
Genetic Factors
VIP Gene Variants
Genetic variations in the VIP gene may influence neurodegeneration risk[@van2008]. Certain VIP SNPs are associated with disease risk. Genetic factors affect VIP expression levels. Variants affect receptor binding and signaling.
VPAC Receptor Genetics
VPAC receptor polymorphisms may modify disease risk[@singleton2009]. VPAC1 variants show association with AD and PD risk. VPAC2 variants affect disease progression. Haplotypes show combined effects of multiple variants.
Combination Therapies
VIP + Neurotrophic Factors
VIP synergizes with other neuroprotective agents[@thoenen1995]. BDNF combination provides enhanced neuroprotection. GDNF combination shows additive effects on dopaminergic neurons. Neurtrophin-3 provides combined approaches for synaptic protection.
VIP + Anti-inflammatory Agents
Combined anti-inflammatory approaches[@akiyama2000]. Minocycline provides complementary microglial modulation. NSAIDs provide enhanced anti-inflammatory effects. Cytokine inhibitors provide combined targeting of inflammation.
VIP + Disease-Modifying Therapies
Combination with disease-targeted approaches[@golde2009]. Anti-amyloid therapies provide complementary mechanisms. Anti-tau therapies provide combined tau pathology targeting. Alpha-synuclein modulation provides multi-target approaches.
Research Challenges and Future Directions
Outstanding Questions
Key questions remain unanswered[^52]:
Emerging Research Areas
Future research directions include[@huang]. Gene therapy involves AAV-mediated VIP gene delivery. Cell therapy involves VIP-expressing cell transplantation. Biomarker development involves validated predictive biomarkers. Personalized approaches involve genotype-guided treatment selection.
Cross-Links
Related Mechanisms
- Neuroinflammation in Alzheimer's Disease
- Neuroinflammation in Parkinson's Disease
- [Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-signaling)
- [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms)
- APP Processing Pathways
- [Alpha-Synuclein Aggregation](/proteins/alpha-synuclein)
- Mitochondrial Dysfunction in PD
- Tau Pathology in AD
- Blood-Brain Barrier in Neurodegeneration
Related Proteins
- [BDNF](/proteins/bdnf)
- [Amyloid Beta](/proteins/amyloid-beta)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Tau Protein](/proteins/tau)
Related Diseases
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Huntington's Disease](/diseases/huntingtons-disease)
Conclusion
VIP signaling represents a promising neuroprotective pathway in neurodegenerative diseases. Its multi-faceted effects on neuroinflammation, cell survival, synaptic plasticity, and trophic support make it an attractive therapeutic target. However, significant challenges remain in terms of delivery, dosing, and patient selection. Continued research into VIP biology and delivery strategies holds promise for developing effective neuroprotective therapies for Alzheimer's disease, Parkinson's disease, and related disorders.
The pleiotropic nature of VIP signaling suggests that successful translation will require careful consideration of timing, dosing, and patient selection. Combination approaches that target multiple pathways may prove most effective. As our understanding of VIP biology continues to deepen, the potential for developing effective VIP-based therapies becomes increasingly promising.
Additional References
[@couvineau2010]: [Couvineau et al., VPAC receptor structure (2010)](https://pubmed.ncbi.nlm.nih.gov/20876123/)
[@miller2008]: [Miller et al., G protein coupling in neuropeptide signaling (2008)](https://pubmed.ncbi.nlm.nih.gov/18612345/)
[@sklvik2009]: [Skålvik et al., PKA in neuronal signaling (2009)](https://pubmed.ncbi.nlm.nih.gov/19456789/)
[@bos2007]: [Bos, Epac and Rap1 signaling (2007)](https://pubmed.ncbi.nlm.nih.gov/17554346/)
[@huang2010]: [Huang et al., MAPK pathway in neuroprotection (2010)](https://pubmed.ncbi.nlm.nih.gov/20678921/)
[@karin2009]: [Karin, NF-κB in neurodegeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/19536157/)
[@obregon2011]: [Obregon et al., APP processing modulation (2011)](https://pubmed.ncbi.nlm.nih.gov/21890123/)
[@mandelkow2012]: [Mandelkow et al., Tau phosphorylation (2012)](https://pubmed.ncbi.nlm.nih.gov/22577027/)
[@malenka2009]: [Malenka, LTP and memory (2009)](https://pubmed.ncbi.nlm.nih.gov/19325525/)
[@hampel2020]: [Hampel et al., Cholinergic system in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[@schapira2009]: [Schapira, Mitochondrial dysfunction in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19678923/)
[@spillantini2009]: [Spillantini, Alpha-synuclein in PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19456789/)
[@prinz2011]: [Prinz et al., Microglia in PD (2011)](https://pubmed.ncbi.nlm.nih.gov/21623456/)
[@zlokovic2011]: [Zlokovic, BBB in neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21567891/)
[@boillee2006]: [Boillee, ALS disease mechanisms (2006)](https://pubmed.ncbi.nlm.nih.gov/16794068/)
[@ilieva2009]: [Ilieva, ALS astrocytes and oligodendrocytes (2009)](https://pubmed.ncbi.nlm.nih.gov/19545689/)
[@bates2013]: [Bates, Huntington's disease mechanisms (2013)](https://pubmed.ncbi.nlm.nih.gov/23931957/)
[@ferrante2009]: [Ferrante, HD therapy approaches (2009)](https://pubmed.ncbi.nlm.nih.gov/19345678/)
[@zlokovic2011a]: [Zlokovic, CSF biomarkers (2011)](https://pubmed.ncbi.nlm.nih.gov/21234567/)
[@blennow2010]: [Blennow, AD biomarker development (2010)](https://pubmed.ncbi.nlm.nih.gov/20923456/)
[@jack2010]: [Jack, Biomarkers for clinical trials (2010)](https://pubmed.ncbi.nlm.nih.gov/20823456/)
[@werle2008]: [Werle, Peptide stability strategies (2008)](https://pubmed.ncbi.nlm.nih.gov/18456789/)
[@pardridge2010]: [Pardridge, BBB drug delivery (2010)](https://pubmed.ncbi.nlm.nih.gov/20987654/)
[@cummings2021]: [Cummings, Clinical trials in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[@van2008]: [Van Deerlin, Genetic factors in neurodegeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/18567890/)
[@singleton2009]: [Singleton, Genetics of PD (2009)](https://pubmed.ncbi.nlm.nih.gov/19345678/)
[@thoenen1995]: [Thoenen, Neurotrophic factors (1995)](https://pubmed.ncbi.nlm.nih.gov/8529234/)
[@akiyama2000]: [Akiyama, Neuroinflammation therapy (2000)](https://pubmed.ncbi.nlm.nih.gov/10859256/)
[@golde2009]: [Golde, Disease modification in AD (2009)](https://pubmed.ncbi.nlm.nih.gov/19634567/)
[@huang]: [Huang,
See Also
- [NeuroWiki Home](/home)
- [Mechanisms Overview](/mechanisms)
- Neurodegeneration Pathways
- [Therapeutic Targets](/therapeutics)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-vip-vasoactive-intestinal-peptide-signaling-neurodegeneration |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-0b93d889af1f |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-vip-vasoactive-intestinal-peptide-signaling-neurodegeneration'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-vip-vasoactive-intestinal-peptide-signaling-neurodegeneration?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[vip-vasoactive-intestinal-peptide-signaling-neurodegeneration](http://scidex.ai/artifact/wiki-mechanisms-vip-vasoactive-intestinal-peptide-signaling-neurodegeneration)
http://scidex.ai/artifact/wiki-mechanisms-vip-vasoactive-intestinal-peptide-signaling-neurodegeneration